Gilead Sciences, Inc. bought $1.8M of Xilio Therapeutics (XLO)

Executed Dec 18 2024, disclosed Dec 19 2024, 1 day later.

Value, as filed

$1.8M

1,759,978 sh × $1.04

Executed

Dec 18 2024

the trade date, as filed

Disclosed

Dec 19 2024

1 day after the trade

Return, 21 sessionsiFrom the disclosed entry session; derived

-6.0%

+46.0% from execution

Over the 21 trading sessions from the disclosed entry session (Dec 19 2024), the stock returned -6.0% (delay-adjusted); from the execution session (Dec 18 2024), +46.0%. Derived: entry at the session's open, exit at the close 20 sessions later.

The filer

GI Gilead Sciences, Inc. 10% owner profile →

Gilead Sciences, Inc. (10% owner) filed 1 Form 4 report as a reporting entity in the trailing twelve months (1 purchase, 0 sales, 1 filed past the two-business-day deadline), most often in ASMB. Across 1 priced purchase filing, the average 21-session return was +7.0% from execution and +30.6% from disclosure (delay-adjusted; derived). The median gap between execution and disclosure was 56 days.

The name

XLO XLO XLO · 1 filing in 24 months ticker → Insider filings, newest first→ View the original filing at www.sec.gov→